First experience with Oasis Collagen SOFT SHIELD


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 30 05 2018
accepted: 31 12 2018
pubmed: 19 1 2019
medline: 18 1 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

To investigate response of dissolving collagen contact lenses as an alternative for bandage contact lenses, for the post-interventional care of epithelial defects after corneal cross-linking (CXL) treatment for keratoconus. Follow-up visits were performed at day 1, 4 and 1 month after the intervention. We reviewed notes for re-epithelialization, comfort/pain and any untoward effects of Collagen SOFT SHIELD Thirty consecutive CXL patients with collagen shield application after CXL were included. Mean age was 28 years (range from 16 to 51 years old). Pre-CXL VA was 0.7 logMAR IQR 0.4-1.0; post-CXL VA at day 4 and month 1 was 0.6 logMAR IQR 0.4-0.9. Post-operative mean SE was 5.5D ± 4.1D. In all patients, the Collagen SOFT SHIELD This study indicates that Oasis Collagen SOFT SHIELD

Sections du résumé

BACKGROUND BACKGROUND
To investigate response of dissolving collagen contact lenses as an alternative for bandage contact lenses, for the post-interventional care of epithelial defects after corneal cross-linking (CXL) treatment for keratoconus.
PATIENTS AND METHODS METHODS
Follow-up visits were performed at day 1, 4 and 1 month after the intervention. We reviewed notes for re-epithelialization, comfort/pain and any untoward effects of Collagen SOFT SHIELD
RESULTS RESULTS
Thirty consecutive CXL patients with collagen shield application after CXL were included. Mean age was 28 years (range from 16 to 51 years old). Pre-CXL VA was 0.7 logMAR IQR 0.4-1.0; post-CXL VA at day 4 and month 1 was 0.6 logMAR IQR 0.4-0.9. Post-operative mean SE was 5.5D ± 4.1D. In all patients, the Collagen SOFT SHIELD
CONCLUSIONS CONCLUSIONS
This study indicates that Oasis Collagen SOFT SHIELD

Identifiants

pubmed: 30656511
doi: 10.1007/s10792-018-01070-9
pii: 10.1007/s10792-018-01070-9
doi:

Substances chimiques

Cross-Linking Reagents 0
Photosensitizing Agents 0
Collagen 9007-34-5

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

2149-2151

Références

Graefes Arch Clin Exp Ophthalmol. 2013 Mar;251(3):803-7
pubmed: 22892583
J Cataract Refract Surg. 2009 Apr;35(4):788-91
pubmed: 19304108
J Cataract Refract Surg. 2010 Mar;36(3):517-20
pubmed: 20202556
Pharm Dev Technol. 2018 Mar;23(3):255-260
pubmed: 28875742
Surv Ophthalmol. 2002 Mar-Apr;47(2):174-82
pubmed: 11918897
Eye Contact Lens. 2018 Nov;44 Suppl 2:S143-S147
pubmed: 28945653

Auteurs

Ivo Guber (I)

Queen Victoria Hospital, NHS Foundation Trust, East Grinstead, West Sussex, UK. ivo.guber@augenchirurgie.ch.
Department of Ophthalmology, University of Geneva, Rue de Alcide-Jentzer 22, 1205, Geneva, Switzerland. ivo.guber@augenchirurgie.ch.

Ciara Bergin (C)

Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.

Shruti Malde (S)

Queen Victoria Hospital, NHS Foundation Trust, East Grinstead, West Sussex, UK.

Josef Guber (J)

Department of Ophthalmology, University of Basel, Basel, Switzerland.

Samer Hamada (S)

Queen Victoria Hospital, NHS Foundation Trust, East Grinstead, West Sussex, UK.

Damian Lake (D)

Queen Victoria Hospital, NHS Foundation Trust, East Grinstead, West Sussex, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH